Advertisement


William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates

NCCN Annual Conference 2019

Advertisement

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses evidence-based first-line treatment options for patients with advanced hormone receptor–positive, HER2-negative breast cancer and toxicities associated with the various therapeutic options.



Related Videos

Hematologic Malignancies

Gary H. Lyman, MD, MPH, on Myeloid Growth Factors: New Biosimilar Approvals

Gary H. Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, discusses current strategies for the use of biosimilars to treat cancer-in...

Colorectal Cancer

Wells A. Messersmith, MD, on Managing Metastatic Colorectal Cancer: NCCN Guidelines Update

Wells A. Messersmith, MD, of the University of Colorado Cancer Center, discusses results of recent clinical trials, emerging treatment options, and approaches that may improv...

Supportive Care

Michelle B. Riba, MD, on Screening for Distress in Cancer: Implementing the Standard of Care

Michelle B. Riba, MD, of the University of Michigan Rogel Cancer Center, discusses the prevalence of distress in patients with cancer, the need for a quick and simple screeni...

Pancreatic Cancer

Margaret A. Tempero, MD, on Pancreatic Cancer: NCCN Guidelines Updates

Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new adjuvant therapy options for patients with pancreatic cancer, and germline testi...

Immunotherapy
Leukemia
Lymphoma

Frederick L. Locke, MD, on Innovative CAR-T Cell Therapies: The Patient Experience

Frederick L. Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses recent approvals of chimeric antigen receptor T-cell therapies in leukemia and l...

Advertisement

Advertisement



;
Advertisement